Using nanopocket membranes to capture bacterial outer membrane vesicles from biofluids
使用纳米袋膜从生物液中捕获细菌外膜囊泡
基本信息
- 批准号:10288527
- 负责人:
- 金额:$ 23.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-09 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:APACHE IIAgeAlbuminsAntibioticsAntibodiesAntigensBacteriaBenchmarkingBiologicalBiological MarkersCause of DeathCellsChronicClinicalClinical DataComplexCritical CareCulture MediaDevelopmentDiagnosisDiagnosticDiagnostic ProcedureDiagnostic testsEarly treatmentEnterobacteriaceaeEscherichia coliFiltrationFocal InfectionFutureHealth StatusHospitalsHourHumanImmune responseInfectionInflammatoryLiquid substanceMeasuresMembraneMolecular Diagnostic TestingOrganismOutcomeParentsPatientsPhosphate BufferPhysiciansPhysiologicalPlasmaProteinsRadialRetrospective StudiesSalineSamplingScientistSepsisSeverity of illnessSystemTechniquesTechnologyTestingTissuesUltracentrifugationVariantVesicleWorkdetection methoddiagnostic assaydiagnostic biomarkerextracellular vesiclesmolecular diagnosticsmolecular markermortalitynovelpoint of carepoint-of-care diagnosticspotential biomarkerpressurerapid diagnosisseptic patientssuccesstool
项目摘要
PROJECT SUMMARY
Sepsis is not only the most expensive condition treated in US hospitals, but also a leading cause
of death. Sepsis occurs when host pro-inflammatory immune responses become abnormally
elevated due to a dysregulated or aberrant host-response to infection. Diagnostic methods for
sepsis can vary between hospitals, but often involve scoring systems (e.g. APACHE II and SOFA)
that grade the severity of illness in patients. Many of the altered physiological parameters
measured by these scoring systems are not necessarily specific to sepsis, which makes it difficult
to diagnose sepsis in early stages. Timing of a patient’s sepsis diagnosis is often predictive of
their clinical outcome, underlining the need for a more definitive molecular diagnostic test.
However, a recent study found that in the majority (70.1%) of sepsis cases, a specific causal
organism could not be determined, likely due to aggressive antibiotics or localized infections.
Bacterial outer membrane vesicles (OMVs) are attractive diagnostic biomarkers because of: A)
their abundance and ability to circulate throughout the body and pass tissue barriers more easily
than bacteria themselves; B) their robustness - unlike their bacterial cell “parent,” OMVs can
withstand the inundation of broad-spectrum antibiotics; and C) their unique features that could
allow for differentiation between bacterial species.
The objective of this proposal is two-fold: Identify whether bacterial OMVs could be a molecular
diagnostic biomarker for sepsis and develop a rapid approach to isolate them from patient plasma.
We seek to develop a straightforward high-purity and rapid separation technology that effectively
isolates and purifies OMVs from biofluids, including plasma. We will implement a modified
tangential flow filtration approach, similar to those used by biopharma for high-capacity and high-
yield purification, with a new nanopocket membrane that effectively captures and releases
bacterial OMVs with minimal loss. Success of these aims will pave the way for the future
development of a one-step, point-of-care diagnostic test for sepsis using bacterial OMVs as the
molecular biomarker, as well a more complex diagnostic test that more accurately quantifies OMV
levels in the patient’s biofluids to help direct early treatment and reduce mortality. This project will
be led by an interdisciplinary team of experts in identifying potential biomarkers in E. coli;
membranes, materials, and bioseparations; and a critical care physician scientist.
项目总结
败血症不仅是美国医院治疗费用最高的疾病,也是主要原因
对死亡的恐惧。当宿主的促炎免疫反应异常时,就会发生脓毒症
由于宿主对感染的反应不正常或异常而升高的。用于诊断的方法
败血症因医院而异,但通常涉及评分系统(如APACHE II和SOFA)
对病人病情的严重程度进行分级。许多改变后的生理参数
通过这些评分系统测量的结果不一定是脓毒症的特异性,这使得它很难
对脓毒症进行早期诊断。患者脓毒症诊断的时机通常预示着
他们的临床结果,强调了更明确的分子诊断测试的必要性。
然而,最近的一项研究发现,在大多数(70.1%)脓毒症病例中,特定的原因
细菌无法确定,可能是由于侵略性的抗生素或局部感染。
细菌外膜囊泡(OMV)是很有吸引力的诊断生物标志物,因为:a)
它们的数量和能力在全身循环,更容易通过组织屏障
细菌本身;B)它们的健壮性--不像它们的细菌细胞“母体”,OMV可以
抵御广谱抗生素的淹没;以及c)它们的独特功能,可以
允许不同细菌物种之间的差异。
这项提议有两个目的:确定细菌OMV是否可能是一个分子
脓毒症的诊断生物标志物,并开发一种从患者血浆中分离它们的快速方法。
我们寻求开发一种简单、高纯度和快速有效的分离技术
从生物体液中分离和提纯OMV,包括血浆。我们将实现修改后的
切向流过滤方法,类似于生物制药用于大容量和高密度过滤的方法。
产量净化,使用一种新的纳米囊膜,有效地捕获和释放
损失最小的细菌型OMV。这些目标的成功将为未来铺平道路
以细菌OMV为基础的一步法、一站式败血症诊断试验的研制
分子生物标记物,以及更复杂的诊断测试,更准确地量化OMV
患者体液中的水平,以帮助指导早期治疗和降低死亡率。这个项目将
由一个跨学科的专家小组领导,以确定大肠杆菌中潜在的生物标志物;
膜、材料和生物分离;以及重症监护内科科学家。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS R GABORSKI其他文献
THOMAS R GABORSKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS R GABORSKI', 18)}}的其他基金
Development of size-selective capture and release membranes for purification of extracellular vesicles
开发用于纯化细胞外囊泡的尺寸选择性捕获和释放膜
- 批准号:
10631914 - 财政年份:2022
- 资助金额:
$ 23.26万 - 项目类别:
Development of size-selective capture and release membranes for purification of extracellular vesicles
开发用于纯化细胞外囊泡的尺寸选择性捕获和释放膜
- 批准号:
10432803 - 财政年份:2022
- 资助金额:
$ 23.26万 - 项目类别:
Using nanopocket membranes to capture bacterial outer membrane vesicles from biofluids
使用纳米袋膜从生物液中捕获细菌外膜囊泡
- 批准号:
10425443 - 财政年份:2021
- 资助金额:
$ 23.26万 - 项目类别:
Plasma clearance of water soluble and albumin bound toxins using graphene oxide nanoengineered laminates
使用氧化石墨烯纳米工程层压板清除水溶性和白蛋白结合毒素
- 批准号:
9387567 - 财政年份:2017
- 资助金额:
$ 23.26万 - 项目类别:
Transparent Ultrathin Nanomembranes for Barrier Cell Models and Novel Co-Culture Systems
用于屏障细胞模型和新型共培养系统的透明超薄纳米膜
- 批准号:
9336323 - 财政年份:2016
- 资助金额:
$ 23.26万 - 项目类别:
Nanoporous Membranes for cellular microarrays and in vitro assays
用于细胞微阵列和体外测定的纳米多孔膜
- 批准号:
8200228 - 财政年份:2011
- 资助金额:
$ 23.26万 - 项目类别:
Microfabricated porous TEM grids for improved phase contrast and CryoEM imaging
微加工多孔 TEM 网格可改善相衬和 CryoEM 成像
- 批准号:
8252786 - 财政年份:2011
- 资助金额:
$ 23.26万 - 项目类别:
Nanoporous silicon membranes for protein purification
用于蛋白质纯化的纳米多孔硅膜
- 批准号:
7802530 - 财政年份:2010
- 资助金额:
$ 23.26万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 23.26万 - 项目类别:
Directed Grant